Although EU authorities have formally adopted the International Council for Harmonisation’s controversial guideline on managing post-approval changes of medicines (ICH Q12), its practical implementation remains in limbo as certain aspects of the guideline are not compatible with the current EU legal framework.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?